Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRTC 
PureTech Health PLC (PRTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: PRTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $46
1 Year Target Price $46
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.71% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 388.63M USD | Price to earnings Ratio 9.46 | 1Y Target Price 46 |
Price to earnings Ratio 9.46 | 1Y Target Price 46 | ||
Volume (30-day avg) 2 | Beta 0.82 | 52 Weeks Range 13.30 - 24.99 | Updated Date 09/14/2025 |
52 Weeks Range 13.30 - 24.99 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.7 |
Earnings Date
Report Date 2025-08-28 | When - | Estimate - | Actual -0.19 |
Profitability
Profit Margin 792.96% | Operating Margin (TTM) -2589.52% |
Management Effectiveness
Return on Assets (TTM) -12.95% | Return on Equity (TTM) 9.44% |
Valuation
Trailing PE 9.46 | Forward PE - | Enterprise Value 72743772 | Price to Sales(TTM) 60.81 |
Enterprise Value 72743772 | Price to Sales(TTM) 60.81 | ||
Enterprise Value to Revenue 11.8 | Enterprise Value to EBITDA 1.92 | Shares Outstanding 24168400 | Shares Floating 166986452 |
Shares Outstanding 24168400 | Shares Floating 166986452 | ||
Percent Insiders - | Percent Institutions 1.47 |
Upturn AI SWOT
PureTech Health PLC
Company Overview
History and Background
PureTech Health PLC is a biotherapeutics company focused on developing medicines to address severe diseases. Founded in 2002, it operates through its Founded Entities and internal research and development. It has evolved from a technology sourcing company to a company developing its own pipeline of therapeutics.
Core Business Areas
- Biotherapeutics Development: Focuses on creating and advancing novel therapies, often through its Founded Entities, targeting immunology, inflammation, and brain health.
- Research and Development: Internal R&D efforts focused on identifying and developing new therapeutic approaches, often based on platform technologies.
Leadership and Structure
The leadership team comprises a CEO, CFO, and other key executives. The organizational structure includes departments for research, development, finance, and business development.
Top Products and Market Share
Key Offerings
- Karuna Therapeutics (Acquired by Bristol Myers Squibb): KarXT (xanomeline-trospium) is approved for schizophrenia. PureTech held a significant equity stake in Karuna. Competitors include antipsychotics from Eli Lilly, Johnson & Johnson, and AbbVie. Puretech no longer holds equity since acquisition.
- Vor Biopharma (VOR): Developing engineered hematopoietic stem cells (eHSCs) for the treatment of hematological malignancies. Competitors include companies developing CAR-T therapies such as Novartis and Gilead.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The market is driven by unmet medical needs and technological advancements.
Positioning
PureTech Health PLC is positioned as a biotherapeutics innovator, focusing on creating and developing novel therapies through its unique Founded Entity model. Competitive advantages include its scientific expertise and ability to identify and de-risk promising technologies.
Total Addressable Market (TAM)
The TAM for biotherapeutics is estimated to be in the hundreds of billions of dollars. PureTech Health PLC is positioned to capture a portion of this TAM by developing and commercializing innovative therapies targeting significant unmet medical needs.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise
- Unique Founded Entity model
- Diversified portfolio of therapeutic candidates
- Experienced management team
Weaknesses
- High R&D costs and long development timelines
- Reliance on the success of its Founded Entities
- Limited commercialization capabilities
- Dilution through equity financing
Opportunities
- Advancement of therapeutic candidates through clinical trials
- Potential for strategic partnerships and collaborations
- Expansion into new therapeutic areas
- Acquisition of promising technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent disputes
Competitors and Market Share
Key Competitors
- LLY
- JNJ
- ABBV
- NVS
- GILD
Competitive Landscape
PureTech Health PLC operates in a highly competitive industry, facing competition from larger pharmaceutical companies and other biotechnology firms. Its Founded Entity model provides a unique approach to drug development, but also carries inherent risks.
Major Acquisitions
Karuna Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 14000
- Strategic Rationale: Acquired by Bristol Myers Squibb. PureTech's equity was sold off. Provided substantial return and validation to PureTech's model
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of therapeutic candidates and strategic transactions involving its Founded Entities.
Future Projections: Future growth is expected to be driven by the continued development of its pipeline and potential commercialization of novel therapies. Analyst estimates vary based on pipeline progress and market conditions.
Recent Initiatives: Recent initiatives include advancing key clinical programs, exploring strategic partnerships, and expanding its research and development efforts.
Summary
PureTech Health operates with a unique model through its Founded Entities. Karuna's acquisition validated their model, however, financial results are dynamic and depend on the performance of its holdings. High R&D costs are a major factor to be weary of as well as clinical trail failures, as with any Biotech. Advancing promising therapies remains the primary focus.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PureTech Health PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-11-16 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.puretechhealth.com |
Full time employees 56 | Website https://www.puretechhealth.com | ||
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.